06 November 2026
Kai-Keen Shiu PhD FRCP; CSCO 2026: Immune-Resistant Colorectal Cancer: Making Microsatellite Stable Tumors Immunogenic, Circulating Tumor DNA, Neoadjuvant Immunotherapy
Audio Journal of Oncology Podcast
About
JINAN, China—Biomarker targeting, neoadjuvant immunotherapy and liquid biopsies are among a range of factors promising to make immune-resistant colorectal cancers (such as those with microsatellite stable disease) immunogenic, according to speakers at the Chinese Society of Clinical Oncology 2026 Annual Meeting.
Peter Goodwin talked with one of the lead session speakers: Kai-Keen Shiu PhD FRCP, Consultant Gastrointestinal Medical Oncologist at University College London Hospital and Associate Professor at the UCL Cancer Institute in London, UK.
Peter Goodwin talked with one of the lead session speakers: Kai-Keen Shiu PhD FRCP, Consultant Gastrointestinal Medical Oncologist at University College London Hospital and Associate Professor at the UCL Cancer Institute in London, UK.